CRC

View All

mercks-gefapixant-for-crc-treatment
Will Merck’s P2X3 Receptor Antagonist for Chronic Refractory Cough Treatment Be Able to Turn FDA’s Nay Into Yea?

Patients who are battling this crippling ailment find that chronic refractory cough (CRC), also known as refractory chronic cough (RCC) or unexplained chronic cough (UCC), proves to be a major burden. DelveInsight’s analysis estimates that in the US, there were approximately 12.7 million 12-month prevalent episodes...

Find More

Chronic Refractory Cough Market | Chronic refractory cough Treatment
Chronic Refractory Cough Market and the Monopoly of the Over-The-Counter Drugs

Cough! Cough! Every time something goes down the wrong pipe, we cough it out. Within seconds, it gets normal. We catch flu, or cold, cough accompanies for a week or two. However, what if cough decides to befriend the person for a time period more than usual, say, around eight weeks or more? It can be worrisome, and...

Find More

Delveinsight
Merck; Bayer; Shionogi set to showcase their candidates indicated for Chronic RefractoryCough in the ATS Virtual Conference

Merck’s Gefapixant could become the first drug approved for Chronic Cough ATS 2020 Virtual is happening from August 5 to August 10, and it is exciting to watch major Respiratory /Pulmonary Pharmaceutical companies and their key presentations. Merck is worth mentioning here, as it is presenting key posters and...

Find More